Topical ivermectin improves allergic skin inflammation

Erwan Ventre (1) , Aurore Rozières (2) , Vanina Lenief (3) , Floriane Albert (3) , P. Rossio (4) , Léo Laoubi (3) , D. Dombrowicz (5) , B. Staels (5) , Lauriane Ulmann (6) , V. Julia (4) , E. Vial (4) , A. Jomard (4) , F. Hacini-Rachinel (4) , Jean-François Nicolas (3) , Marc Vocanson (3)

1 Immunité et lymphocytes cytotoxiques – Immunity and cytotoxic lymphocytes
2 APY - Autophagie infection et immunité - Autophagy Infection Immunity
3 Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination
4 Nestle Skin Health GALDERMA R&D
5 RNMCD - Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011
6 IGF - Institut de Génomique Fonctionnelle

BACKGROUND: Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties. METHODS: Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays. RESULTS: Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation. CONCLUSION: Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.

Mots clés: Administration; Topical; Allergens; Animals; Antigens; Dermatophagoides; atopic dermatitis; Cell Line; Cytokines; Dendritic Cells; Dermatitis; Atopic; Disease Models; Animal; Enzyme-Linked Immunospot Assay; Fragile X Mental Retardation Protein; Humans; Inflammation Mediators; Ivermectin; Lymphocyte Activation; Macrophages; Mice; Knockout; Receptors; Purinergic P2X4; skin inflammatory diseases; T-cell immunity; T-Lymphocyte Subsets; topical treatment

Domaines: Immunologie; Bactériologie; Virologie

Erwan Ventre, Aurore Rozières, Vanina Lenief, Floriane Albert, P. Rossio, et al.. Topical ivermectin improves allergic skin inflammation. Allergy, 2017, 72 (8), pp.1212-1221. ⟨10.1111/all.13118⟩. ⟨hal-01911109⟩